Price
CHART BY
Frequently asked questions
What is Genmab's market capitalization?
The market capitalization of Genmab is $12.99B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Genmab's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Genmab is 20.34. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Genmab?
Genmab's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $10.05. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Genmab's stock?
Currently, 29 analysts cover Genmab's stock, with a consensus target price of $347.73. Analyst ratings provide insights into the stock's expected performance.
What is Genmab's revenue over the trailing twelve months?
Over the trailing twelve months, Genmab reported a revenue of $2.76B.
What is the free cash flow of Genmab?
Genmab has a free cash flow of $919.04M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Genmab have, and what sector and industry does it belong to?
Genmab employs approximately 2,204 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.
What is the free float of Genmab's shares?
The free float of Genmab is 60.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $12.99B
- EPS (TTM)
- $10.05
- Free Float
- 60.34M
- P/E ratio (TTM)
- 20.34
- Revenue (TTM)
- $2.76B
- Free Cashflow (TTM)
- $919.04M
Pricing
- 1D span
- $198.02$204.44
- 52W span
- $197.56$327.01
Analyst Ratings
The price target is $347.73 and the stock is covered by 29 analysts.
Buy
18
Hold
10
Sell
1
Information
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
- Employees
- 2,204
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- DK0010272202
- Primary Ticker
- GMAB